Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1993 Jan;35(1):1–7. doi: 10.1111/j.1365-2125.1993.tb05662.x

Isoenzyme selective phosphodiesterase inhibitors: potential clinical uses.

I P Hall 1
PMCID: PMC1381482  PMID: 8383516

Full text

PDF
1

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahn H. S., Crim W., Romano M., Sybertz E., Pitts B. Effects of selective inhibitors on cyclic nucleotide phosphodiesterases of rabbit aorta. Biochem Pharmacol. 1989 Oct 1;38(19):3331–3339. doi: 10.1016/0006-2952(89)90631-x. [DOI] [PubMed] [Google Scholar]
  2. Anderson J. L., Baim D. S., Fein S. A., Goldstein R. A., LeJemtel T. H., Likoff M. J. Efficacy and safety of sustained (48 hour) intravenous infusions of milrinone in patients with severe congestive heart failure: a multicenter study. J Am Coll Cardiol. 1987 Apr;9(4):711–722. doi: 10.1016/s0735-1097(87)80223-1. [DOI] [PubMed] [Google Scholar]
  3. BUTCHER R. W., SUTHERLAND E. W. Adenosine 3',5'-phosphate in biological materials. I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem. 1962 Apr;237:1244–1250. [PubMed] [Google Scholar]
  4. Beavo J. A., Reifsnyder D. H. Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci. 1990 Apr;11(4):150–155. doi: 10.1016/0165-6147(90)90066-H. [DOI] [PubMed] [Google Scholar]
  5. Curfman G. D. Inotropic therapy for heart failure--an unfulfilled promise. N Engl J Med. 1991 Nov 21;325(21):1509–1510. doi: 10.1056/NEJM199111213252111. [DOI] [PubMed] [Google Scholar]
  6. Giembycz M. A. Could isoenzyme-selective phosphodiesterase inhibitors render bronchodilator therapy redundant in the treatment of bronchial asthma? Biochem Pharmacol. 1992 May 28;43(10):2041–2051. doi: 10.1016/0006-2952(92)90160-k. [DOI] [PubMed] [Google Scholar]
  7. Gilman A. G. G proteins: transducers of receptor-generated signals. Annu Rev Biochem. 1987;56:615–649. doi: 10.1146/annurev.bi.56.070187.003151. [DOI] [PubMed] [Google Scholar]
  8. Green R. D., Stanberry L. R. Elevation of cyclic AMP in C-1300 murine neuroblastoma by adenosine and related compounds and the antagonism of this response by methylxanthines. Biochem Pharmacol. 1977 Jan 1;26(1):37–43. doi: 10.1016/0006-2952(77)90127-7. [DOI] [PubMed] [Google Scholar]
  9. Gristwood R. W., Eden R. J., Owen D. A., Taylor E. M. Pharmacological studies with SK&F 94120, a novel positive inotropic agent with vasodilator activity. J Pharm Pharmacol. 1986 Jun;38(6):452–459. doi: 10.1111/j.2042-7158.1986.tb04609.x. [DOI] [PubMed] [Google Scholar]
  10. Hall I. P., Donaldson J., Hill S. J. Inhibition of histamine-stimulated inositol phospholipid hydrolysis by agents which increase cyclic AMP levels in bovine tracheal smooth muscle. Br J Pharmacol. 1989 Jun;97(2):603–613. doi: 10.1111/j.1476-5381.1989.tb11992.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hall I. P., Donaldson J., Hill S. J. Modulation of carbachol-induced inositol phosphate formation in bovine tracheal smooth muscle by cyclic AMP phosphodiesterase inhibitors. Biochem Pharmacol. 1990 Apr 15;39(8):1357–1363. doi: 10.1016/0006-2952(90)90013-b. [DOI] [PubMed] [Google Scholar]
  12. Hansen R. S., Beavo J. A. Purification of two calcium/calmodulin-dependent forms of cyclic nucleotide phosphodiesterase by using conformation-specific monoclonal antibody chromatography. Proc Natl Acad Sci U S A. 1982 May;79(9):2788–2792. doi: 10.1073/pnas.79.9.2788. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Harris A. L., Connell M. J., Ferguson E. W., Wallace A. M., Gordon R. J., Pagani E. D., Silver P. J. Role of low Km cyclic AMP phosphodiesterase inhibition in tracheal relaxation and bronchodilation in the guinea pig. J Pharmacol Exp Ther. 1989 Oct;251(1):199–206. [PubMed] [Google Scholar]
  14. Heaslip R. J., Giesa F. R., Rimele T. J., Grimes D. Co-regulation of tracheal tone by cyclic AMP- and cyclic GMP-dependent mechanisms. J Pharmacol Exp Ther. 1987 Dec;243(3):1018–1026. [PubMed] [Google Scholar]
  15. Hill S. J., Kendall D. A. Cross-talk between different receptor-effector systems in the mammalian CNS. Cell Signal. 1989;1(2):135–141. doi: 10.1016/0898-6568(89)90002-8. [DOI] [PubMed] [Google Scholar]
  16. Hurwitz R. L., Bunt-Milam A. H., Chang M. L., Beavo J. A. cGMP phosphodiesterase in rod and cone outer segments of the retina. J Biol Chem. 1985 Jan 10;260(1):568–573. [PubMed] [Google Scholar]
  17. Jaski B. E., Fifer M. A., Wright R. F., Braunwald E., Colucci W. S. Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J Clin Invest. 1985 Feb;75(2):643–649. doi: 10.1172/JCI111742. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kauffman R. F., Crowe V. G., Utterback B. G., Robertson D. W. LY195115: a potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum. Mol Pharmacol. 1986 Dec;30(6):609–616. [PubMed] [Google Scholar]
  19. Kauffman R. F., Schenck K. W., Utterback B. G., Crowe V. G., Cohen M. L. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides. J Pharmacol Exp Ther. 1987 Sep;242(3):864–872. [PubMed] [Google Scholar]
  20. Kehr W., Debus G., Neumeister R. Effects of rolipram, a novel antidepressant, on monoamine metabolism in rat brain. J Neural Transm. 1985;63(1):1–12. doi: 10.1007/BF01249580. [DOI] [PubMed] [Google Scholar]
  21. Kereiakes D., Chatterjee K., Parmley W. W., Atherton B., Curran D., Kereiakes A., Spangenberg R. Intravenous and oral MDL 17043 (a new inotrope-vasodilator agent) in congestive heart failure: hemodynamic and clinical evaluation in 38 patients. J Am Coll Cardiol. 1984 Nov;4(5):884–889. doi: 10.1016/s0735-1097(84)80047-9. [DOI] [PubMed] [Google Scholar]
  22. Kincaid R. L., Balaban C. D., Billingsley M. L. Differential localization of calmodulin-dependent enzymes in rat brain: evidence for selective expression of cyclic nucleotide phosphodiesterase in specific neurons. Proc Natl Acad Sci U S A. 1987 Feb;84(4):1118–1122. doi: 10.1073/pnas.84.4.1118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Kincaid R. L., Balaban C. D., Billingsley M. L. Regulated expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in the central nervous system. J Cyclic Nucleotide Protein Phosphor Res. 1986;11(7):473–486. [PubMed] [Google Scholar]
  24. Leeman M., Lejeune P., Melot C., Naeije R. Reduction in pulmonary hypertension and in airway resistances by enoximone (MDL 17,043) in decompensated COPD. Chest. 1987 May;91(5):662–666. doi: 10.1378/chest.91.5.662. [DOI] [PubMed] [Google Scholar]
  25. Lugnier C., Schoeffter P., Le Bec A., Strouthou E., Stoclet J. C. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol. 1986 May 15;35(10):1743–1751. doi: 10.1016/0006-2952(86)90333-3. [DOI] [PubMed] [Google Scholar]
  26. Marangos P. J., Houston M., Montgomery P. [3H]dipyridamole: a new ligand probe for brain adenosine uptake sites. Eur J Pharmacol. 1985 Nov 19;117(3):393–394. doi: 10.1016/0014-2999(85)90017-2. [DOI] [PubMed] [Google Scholar]
  27. Maurice D. H., Haslam R. J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol. 1990 May;37(5):671–681. [PubMed] [Google Scholar]
  28. Murray K. J., England P. J., Hallam T. J., Maguire J., Moores K., Reeves M. L., Simpson A. W., Rink T. J. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function. Br J Pharmacol. 1990 Mar;99(3):612–616. doi: 10.1111/j.1476-5381.1990.tb12978.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nicholson C. D., Challiss R. A., Shahid M. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci. 1991 Jan;12(1):19–27. doi: 10.1016/0165-6147(91)90484-a. [DOI] [PubMed] [Google Scholar]
  30. Nielson C. P., Vestal R. E., Sturm R. J., Heaslip R. Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leukocyte respiratory burst. J Allergy Clin Immunol. 1990 Nov;86(5):801–808. doi: 10.1016/s0091-6749(05)80186-1. [DOI] [PubMed] [Google Scholar]
  31. Packer M., Carver J. R., Rodeheffer R. J., Ivanhoe R. J., DiBianco R., Zeldis S. M., Hendrix G. H., Bommer W. J., Elkayam U., Kukin M. L. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med. 1991 Nov 21;325(21):1468–1475. doi: 10.1056/NEJM199111213252103. [DOI] [PubMed] [Google Scholar]
  32. Plaut M., Marone G., Gillespie E. The role of cyclic AMP in modulating cytotoxic T lymphocytes. II. Sequential changes during culture in responsiveness of cytotoxic lymphocytes to cyclic AMP-active agents. J Immunol. 1983 Dec;131(6):2945–2952. [PubMed] [Google Scholar]
  33. Pyne N. J., Anderson N., Lavan B. E., Milligan G., Nimmo H. G., Houslay M. D. Specific antibodies and the selective inhibitor ICI 118233 demonstrate that the hormonally stimulated 'dense-vesicle' and peripheral-plasma-membrane cyclic AMP phosphodiesterases display distinct tissue distributions in the rat. Biochem J. 1987 Dec 15;248(3):897–901. doi: 10.1042/bj2480897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Ramkumar V., Stiles G. L. A novel site of action of a high affinity A1 adenosine receptor antagonist. Biochem Biophys Res Commun. 1988 Jun 30;153(3):939–944. doi: 10.1016/s0006-291x(88)81318-4. [DOI] [PubMed] [Google Scholar]
  35. Reeves M. L., Leigh B. K., England P. J. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Implications for the mechanism of action of selective phosphodiesterase inhibitors. Biochem J. 1987 Jan 15;241(2):535–541. doi: 10.1042/bj2410535. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Robicsek S. A., Krzanowski J. J., Szentivanyi A., Polson J. B. High pressure liquid chromatography of cyclic nucleotide phosphodiesterase from purified human T-lymphocytes. Biochem Biophys Res Commun. 1989 Aug 30;163(1):554–560. doi: 10.1016/0006-291x(89)92173-6. [DOI] [PubMed] [Google Scholar]
  37. Schneider H. H., Schmiechen R., Brezinski M., Seidler J. Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur J Pharmacol. 1986 Aug 7;127(1-2):105–115. doi: 10.1016/0014-2999(86)90210-4. [DOI] [PubMed] [Google Scholar]
  38. Schwabe U., Trost T. Characterization of adenosine receptors in rat brain by (-)[3H]N6-phenylisopropyladenosine. Naunyn Schmiedebergs Arch Pharmacol. 1980 Sep;313(3):179–187. doi: 10.1007/BF00505731. [DOI] [PubMed] [Google Scholar]
  39. Silver P. J., Hamel L. T., Perrone M. H., Bentley R. G., Bushover C. R., Evans D. B. Differential pharmacologic sensitivity of cyclic nucleotide phosphodiesterase isozymes isolated from cardiac muscle, arterial and airway smooth muscle. Eur J Pharmacol. 1988 May 20;150(1-2):85–94. doi: 10.1016/0014-2999(88)90753-4. [DOI] [PubMed] [Google Scholar]
  40. Simpson A. W., Reeves M. L., Rink T. J. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets. Biochem Pharmacol. 1988 Jun 15;37(12):2315–2320. doi: 10.1016/0006-2952(88)90357-7. [DOI] [PubMed] [Google Scholar]
  41. Thompson W. J. Cyclic nucleotide phosphodiesterases: pharmacology, biochemistry and function. Pharmacol Ther. 1991;51(1):13–33. doi: 10.1016/0163-7258(91)90039-o. [DOI] [PubMed] [Google Scholar]
  42. Torphy T. J., Burman M., Huang L. B., Tucker S. S. Inhibition of the low km cyclic AMP phosphodiesterase in intact canine trachealis by SK&F 94836: mechanical and biochemical responses. J Pharmacol Exp Ther. 1988 Sep;246(3):843–850. [PubMed] [Google Scholar]
  43. Torphy T. J., Undem B. J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 1991 Jul;46(7):512–523. doi: 10.1136/thx.46.7.512. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wachtel H. Neurotropic effects of the optical isomers of the selective adenosine cyclic 3',5'-monophosphate phosphodiesterase inhibitor rolipram in rats in-vivo. J Pharm Pharmacol. 1983 Jul;35(7):440–444. doi: 10.1111/j.2042-7158.1983.tb04318.x. [DOI] [PubMed] [Google Scholar]
  45. Wright C. D., Kuipers P. J., Kobylarz-Singer D., Devall L. J., Klinkefus B. A., Weishaar R. E. Differential inhibition of human neutrophil functions. Role of cyclic AMP-specific, cyclic GMP-insensitive phosphodiesterase. Biochem Pharmacol. 1990 Aug 15;40(4):699–707. doi: 10.1016/0006-2952(90)90304-4. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES